Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled time : 12:00 save search
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
Published: 2023-12-04 (Crawled : 12:00) - globenewswire.com
APLM | $0.531 -1.69% -1.71% 100K
|
n/a
|
| O: 2.53%
H: 0.22%
C: -17.21%
ongoing trials phase 2
Telesat Government Solutions Awarded DARPA Space-BACN Phase 2 Contract
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
TSAT | $7.97 0.63% 0.63% 27K
|
|
| O: 0.28%
H: 5.81%
C: 3.46%
contract solutions phase 2
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
SKYE | $9.17 -20.98% 27K
|
Transportation and Warehousing
|
| O: 3.23%
H: 6.25%
C: -3.13%
sbi-100 glaucoma bioscience study phase 2
Akoustis Awarded Phase 2 For DARPA COFFEE Program
Published: 2023-11-16 (Crawled : 12:00) - globenewswire.com
AKTS | $0.5048 -0.06% -0.06% 360K
|
Electronic Technology
|
| O: 9.51%
H: 0.27%
C: -16.89%
program phase 2
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
CLDX | News | $39.66 2.75% 2.67% 910K
|
Health Technology
|
| O: 26.94%
H: 1.73%
C: -11.01%
urticaria positive topline therapeutics results study phase 2
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
OCUP | $1.745 0.29% 0.29% 92K
|
Health Technology
|
| O: 5.23%
H: 2.65%
C: -8.94%
apx3330 fda pharma meeting diabetic phase 2
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
LIFE | $1.59 -1.24% -1.26% 540K
|
Health Technology
|
| O: -0.8%
H: 2.42%
C: 0.81%
pharma efzofitimod study phase 2
Hycroft Mining Finds Elevated Silver Across the Hycroft System in Phase 2 Drilling
Published: 2023-10-23 (Crawled : 12:00) - prnewswire.com
HYMC | $3.69 -1.86% -1.9% 550K
|
Non-Energy Minerals
|
| O: 2.31%
H: 4.6%
C: 4.6%
system mining phase 2
HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME
Published: 2023-10-05 (Crawled : 12:00) - prnewswire.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -3.56%
H: 4.1%
C: 2.46%
HRMY | $29.19 -1.98% -2.02% 330K
|
Health Technology
|
| O: 0.41%
H: 1.63%
C: 1.03%
study phase 2
Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
Published: 2023-10-02 (Crawled : 12:00) - globenewswire.com
ZVRA | $4.66 -2.31% -2.36% 210K
|
n/a
|
| O: 0.0%
H: 0.83%
C: -2.07%
kp1077 trial therapeutics phase 2
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Published: 2023-09-18 (Crawled : 12:00) - globenewswire.com
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
|
| O: 2.36%
H: 6.15%
C: -1.46%
pharmaceuticals trial phase 2
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Published: 2023-09-12 (Crawled : 12:00) - globenewswire.com
ALT | $7.05 -6.25% -6.67% 3.6M
|
Commercial Services
|
| O: 0.82%
H: 7.76%
C: 6.53%
obesity momentum trial phase 2
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
Published: 2023-09-07 (Crawled : 12:00) - globenewswire.com
FDMT | $25.3 -5.42% -5.73% 520K
|
Health Technology
|
| O: -1.39%
H: 2.5%
C: 1.02%
prism expansion trial phase 2
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
Published: 2023-08-23 (Crawled : 12:00) - globenewswire.com
ONVO | $1.165 1.3% 1.29% 540K
|
Health Technology
|
| O: 6.98%
H: 0.0%
C: -1.45%
fxr314 nash phase 2
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
Published: 2023-08-17 (Crawled : 12:00) - biospace.com/
IMUX | $1.225 -4.3% -4.49% 180K
|
Health Technology
|
| O: 1.82%
H: 1.23%
C: -4.76%
sclerosis trial phase 2
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
ELOX | $0.9874 -51.57% 93K
|
Health Technology
|
| O: 5.05%
H: 20.04%
C: 14.83%
elx-02 drug pharmaceuticals response study phase 2
Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
Published: 2023-08-09 (Crawled : 12:00) - globenewswire.com
PALI | $6.54 10.29% 9.33% 1.6M
|
Manufacturing
|
| O: -69.07%
H: 22.78%
C: 20.62%
lb1148 topline results study phase 2
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
Published: 2023-08-03 (Crawled : 12:00) - biospace.com/
BOLT | $1.12 -2.61% -2.68% 74K
|
|
| O: 0.77%
H: 3.82%
C: 0.0%
bdc-1001 cancer phase 2
Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair
Published: 2023-07-26 (Crawled : 12:00) - globenewswire.com
HUMA | $3.13 2.29% 2.24% 1.1M
|
Manufacturing
|
| O: 0.0%
H: 3.83%
C: 1.39%
trial phase 2
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
Published: 2023-07-06 (Crawled : 12:00) - globenewswire.com
CLDX | News | $39.66 2.75% 2.67% 910K
|
Health Technology
|
| O: -0.54%
H: 2.14%
C: 1.4%
study phase 2
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.